BIIB
Biogen Inc.
$193.45
+1.08%
2026-05-08
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
P/E Ratio
20.49
Forward P/E
11.54
EPS (TTM)
$9.30
ROE
7.7%
Revenue Growth (YoY)
1.9%
Profit Margin
13.8%
Debt/Equity
35.18
Price/Book
1.51
Beta
0.20
Market Cap
$28.14B
Avg Volume (10D)
1.0M
Recent Breakout Signals
No recent breakout signals detected for BIIB.
Recent Price Range (60 Days)
60D High
$200.29
60D Low
$168.64
Avg Volume
1.0M
Latest Close
$193.45
Get breakout alerts for BIIB
Sign up for Breakout Scanner to receive daily notifications when BIIB triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Biogen Inc. (BIIB) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors BIIB daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BIIB operates in the Healthcare sector within the Drug Manufacturers - General industry. Data is provided for informational purposes only and does not constitute financial advice.